Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Avidity Biosciences stock | $33.32

Own Avidity Biosciences stock in just a few minutes.

Fact checked

Avidity Biosciences, Inc is a biotechnology business based in the US. Avidity Biosciences shares (RNA) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Avidity Biosciences

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Avidity Biosciences. Find the stock by name or ticker symbol: RNA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Avidity Biosciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$33.32, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Avidity Biosciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Avidity Biosciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Avidity Biosciences share price

Use our graph to track the performance of RNA stocks over time.

Avidity Biosciences shares at a glance

Information last updated 2020-12-03.
Latest market closeUSD$33.32
52-week rangeUSD$23.06 - USD$37.46
50-day moving average USD$28.4546
200-day moving average USD$28.7666
Wall St. target priceUSD$43.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1

Buy Avidity Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Avidity Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Avidity Biosciences price performance over time

Historical closes compared with the close of $33.32 from 2020-12-09

1 week (2021-01-07) 31.60%
1 month (2020-12-15) 3.09%
3 months (2020-10-15) 19.77%
6 months (2020-07-15) 26.40%
1 year (2020-01-13) N/A
2 years (2019-01-13) N/A
3 years (2018-01-13) N/A
5 years (2016-01-13) N/A

Avidity Biosciences financials

Revenue TTM USD$6.1 million
Gross profit TTM USD$-12,220,000
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value $0
Market capitalisation USD$1.1 billion

TTM: trailing 12 months

Shorting Avidity Biosciences shares

There are currently 1.6 million Avidity Biosciences shares held short by investors – that's known as Avidity Biosciences's "short interest". This figure is 10.9% up from 1.4 million last month.

There are a few different ways that this level of interest in shorting Avidity Biosciences shares can be evaluated.

Avidity Biosciences's "short interest ratio" (SIR)

Avidity Biosciences's "short interest ratio" (SIR) is the quantity of Avidity Biosciences shares currently shorted divided by the average quantity of Avidity Biosciences shares traded daily (recently around 133094.38390612). Avidity Biosciences's SIR currently stands at 11.93. In other words for every 100,000 Avidity Biosciences shares traded daily on the market, roughly 11930 shares are currently held short.

However Avidity Biosciences's short interest can also be evaluated against the total number of Avidity Biosciences shares, or, against the total number of tradable Avidity Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Avidity Biosciences's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Avidity Biosciences shares in existence, roughly 40 shares are currently held short) or 0.0508% of the tradable shares (for every 100,000 tradable Avidity Biosciences shares, roughly 51 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Avidity Biosciences.

Find out more about how you can short Avidity Biosciences stock.

Avidity Biosciences share dividends

We're not expecting Avidity Biosciences to pay a dividend over the next 12 months.

Avidity Biosciences overview

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of muscle atrophy, duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe diseases. Avidity Biosciences, Inc. was founded in 2012 and is based in La Jolla, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site